<DOC>
	<DOCNO>NCT00396591</DOCNO>
	<brief_summary>The primary objective study compare time paracenteses administration Aflibercept ( ziv-aflibercept , AVE0005 , VEGF trap , ZALTRAPÂ® ) ovarian cancer participant symptomatic malignant ascites . The secondary objective assess efficacy safety Aflibercept treatment , exploratory objective assess pharmacokinetics , immunogenicity health-related quality life .</brief_summary>
	<brief_title>AVE0005 ( VEGF Trap ) Patients With Recurrent Symptomatic Malignant Ascites</brief_title>
	<detailed_description>The study consist : - A 30-day screening phase prior Day 1 - Day 1 registration pre-treatment paracentesis - Aflibercept administration within 1-day registration - Two-week study treatment cycle ( efficacy data , cut-off date 6 month post-registration - A 60-day post-treatment follow-up phase During study , participant treat Aflibercept study treatment duration study unless meet one follow criterion discontinuation : - Participant ( legal representative ) choose withdraw treatment - The investigator sponsor think continuation study would detrimental participant well-being - Participant intercurrent illness prevent administration investigational product ( IP ) - Participant 2 IP dose reduction - Participant unacceptable adverse event ( AEs ) - Participant arterial thromboembolic event , include cerebrovascular accident , myocardial infarction , transient ischemic attack , new onset angina , worsen preexist angina - Participant required surgical intervention intestinal obstruction gastrointestinal perforation</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Participants meet follow criterion eligible . Symptomatic malignant ascites result advanced ovarian epithelial cancer ( include fallopian tube primary peritoneal adenocarcinoma ) require least 3 previous therapeutic paracenteses frequency 1 4 paracenteses per month management . Platinum resistant disease define relapse progression disease treatment , drug intolerance . Topotecan and/or liposomal doxorubicinresistant disease define relapse progression disease treatment , drug intolerance . Peritoneovenous type shunt place management ascites Prior treatment VEGF VEGF receptor inhibitor Uncontrolled hypertension The information intend contain consideration relevant participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>malignant ascites</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>angiogenesis inhibition</keyword>
	<keyword>VEGF-Trap fusion recombinant protein</keyword>
</DOC>